Latest news with #VentureCapitalCatalystInitiative
Yahoo
2 days ago
- Business
- Yahoo
Genesys Capital is Closing its Largest Fund to Date – Genesys Ventures IV LP
TORONTO & MONTREAL, June 11, 2025--(BUSINESS WIRE)--Genesys Capital ("Genesys") is pleased to announce the upcoming closing of Genesys Ventures IV LP ("Fund IV" or the "fund") to continue its successful track record of building Canadian life science companies in both the medtech and biotech sectors. Genesys welcomes new Limited Partners into Fund IV and thanks returning LP's that engaged early, maintained unwavering support through the fundraising process, and provided catalytic commitments of scale to the fund, in the current context of an unprecedented, ever-changing macro environment. Fund IV institutional investors include: BDC Capital, Export Development Canada (EDC), Fonds de solidarité de la Fédération des travailleurs et travailleuses du Québec (FTQ), HarbourVest, Royal Bank of Canada, Teralys Capital, Venture Ontario, and the Government of Canada's Venture Capital Catalyst Initiative (VCCI), which is administered by BDC Capital under its Life Sciences Stream. Limited Partner commitment to the Genesys franchise and the Genesys investment thesis of co-creating and investing in disruptive Canadian life science opportunities has paid off as Genesys has delivered class leading performance and increasing DPI across its successive funds. Genesys' value-added, partnership approach to working with scientific founders provides both capital and expertise to create companies that compete on a global scale. This has anchored Genesys as a local trusted source of deal flow for global syndicate partners and a first point of contact for repeat entrepreneurs. The team at Genesys has mastered its strategy that takes advantage of the opportunity that the innovation in Canada provides. Genesys has a distinguished history of delivering upper quartile returns across its previous funds and has stepped up into upper decile in its third fund. Notable recent exits include Inversago Pharma, which was acquired by Novo Nordisk for $1.4 billion, and Fusion Pharmaceuticals, which exited to AstraZeneca for $3.3 billion. These successes highlight Genesys' ability to generate fund level returns driven by local Canadian innovation. With this fund, Genesys Capital will continue to set the standard for life sciences venture capital in Canada, with a commitment to building world-class companies and delivering exceptional returns for its investors. Quotes "EDC is proud to support Genesys Capital, an important funder of companies advancing life sciences in Canada. As healthcare continues its rapid global expansion, Canada stands out with its skilled talent base, early-stage research and development capacity, and strong presence in medtech and biotech. Genesys' approach of building anchor companies will foster enduring ecosystem clusters in Canada, help drive innovation and strengthen Canada's global competitiveness in this growing sector. We look forward to seeing the transformative impact of this fund."Guillermo Freire, Senior Vice-President, Mid-Market Group, EDC. "The Fonds de solidarité FTQ's reinvestment in Genesys Capital demonstrates our confidence in a strategic player in life sciences venture capital. With its in-depth knowledge of the Quebec ecosystem and its ongoing support for emerging local companies in biotechnology, Genesys actively contributes to the sector's competitiveness and innovation."Maxime Pesant, Vice-President, Private Equity and Impact Investing – Life Sciences, at the Fonds de solidarité FTQ. "Accessing Canadian life sciences investments through a long-term partner like Genesys supports innovation in the market. It is also a strategic move to diversify the Canadian economy and ensure global competitiveness in health and biotechnology, sectors that we believe have historically delivered competitive returns for our investors."Senia Rapisarda, Managing Director, HarbourVest Partners. "It is a great time to be investing out of a new fund, and we are looking forward to continuing to create best in class biopharmaceutical and medical technology companies that leverage local innovations."Damian Lamb, Co-founder and Managing Director, Genesys Capital. "We are pleased to recommit to the Genesys team and vision. Ontario is recognized as a leader in the life sciences sector and home to some of the sector's most innovative start-ups. The Genesys team, headquartered in Ontario, has a unique ability to identify high-potential companies and support them in becoming global leaders. We are excited about this continued partnership."Steve Romanyshyn, President and Chief Executive Officer at Venture Ontario. "Congratulations to the Genesys team. The government's approach of co-investing alongside private VC funds through the Venture Capital Catalyst Initiative is helping boost investment in emerging sectors. Today's announcement shows that Canadian life sciences innovation is going strong and getting the support it needs to compete."The Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions. About Genesys Genesys Capital is a Venture Capital Fund based in Toronto, investing in early-stage life sciences opportunities in areas of unmet medical need. With over 25 years of investment experience adhering to a consistent company creation investment strategy, Genesys has become the most successful life sciences venture firm in Canada. Contact: Genesys Capital 123 Front Street West, Suite 1503, Toronto, ON M5J 2M2 info@ View source version on Contacts Jennifer Williamsjen@ (416) 598-4900
Business Wire
2 days ago
- Business
- Business Wire
Genesys Capital is Closing its Largest Fund to Date – Genesys Ventures IV LP
TORONTO & MONTREAL--(BUSINESS WIRE)--Genesys Capital ('Genesys') is pleased to announce the upcoming closing of Genesys Ventures IV LP ('Fund IV' or the 'fund') to continue its successful track record of building Canadian life science companies in both the medtech and biotech sectors. "Accessing Canadian life sciences investments through a long-term partner like Genesys supports innovation in the market." Genesys welcomes new Limited Partners into Fund IV and thanks returning LP's that engaged early, maintained unwavering support through the fundraising process, and provided catalytic commitments of scale to the fund, in the current context of an unprecedented, ever-changing macro environment. Fund IV institutional investors include: BDC Capital, Export Development Canada (EDC), Fonds de solidarité de la Fédération des travailleurs et travailleuses du Québec (FTQ), HarbourVest, Royal Bank of Canada, Teralys Capital, Venture Ontario, and the Government of Canada's Venture Capital Catalyst Initiative (VCCI), which is administered by BDC Capital under its Life Sciences Stream. Limited Partner commitment to the Genesys franchise and the Genesys investment thesis of co-creating and investing in disruptive Canadian life science opportunities has paid off as Genesys has delivered class leading performance and increasing DPI across its successive funds. Genesys' value-added, partnership approach to working with scientific founders provides both capital and expertise to create companies that compete on a global scale. This has anchored Genesys as a local trusted source of deal flow for global syndicate partners and a first point of contact for repeat entrepreneurs. The team at Genesys has mastered its strategy that takes advantage of the opportunity that the innovation in Canada provides. Genesys has a distinguished history of delivering upper quartile returns across its previous funds and has stepped up into upper decile in its third fund. Notable recent exits include Inversago Pharma, which was acquired by Novo Nordisk for $1.4 billion, and Fusion Pharmaceuticals, which exited to AstraZeneca for $3.3 billion. These successes highlight Genesys' ability to generate fund level returns driven by local Canadian innovation. With this fund, Genesys Capital will continue to set the standard for life sciences venture capital in Canada, with a commitment to building world-class companies and delivering exceptional returns for its investors. Quotes 'EDC is proud to support Genesys Capital, an important funder of companies advancing life sciences in Canada. As healthcare continues its rapid global expansion, Canada stands out with its skilled talent base, early-stage research and development capacity, and strong presence in medtech and biotech. Genesys' approach of building anchor companies will foster enduring ecosystem clusters in Canada, help drive innovation and strengthen Canada's global competitiveness in this growing sector. We look forward to seeing the transformative impact of this fund.' Guillermo Freire, Senior Vice-President, Mid-Market Group, EDC. 'The Fonds de solidarité FTQ's reinvestment in Genesys Capital demonstrates our confidence in a strategic player in life sciences venture capital. With its in-depth knowledge of the Quebec ecosystem and its ongoing support for emerging local companies in biotechnology, Genesys actively contributes to the sector's competitiveness and innovation.' Maxime Pesant, Vice-President, Private Equity and Impact Investing – Life Sciences, at the Fonds de solidarité FTQ. 'Accessing Canadian life sciences investments through a long-term partner like Genesys supports innovation in the market. It is also a strategic move to diversify the Canadian economy and ensure global competitiveness in health and biotechnology, sectors that we believe have historically delivered competitive returns for our investors.' Senia Rapisarda, Managing Director, HarbourVest Partners. 'It is a great time to be investing out of a new fund, and we are looking forward to continuing to create best in class biopharmaceutical and medical technology companies that leverage local innovations.' Damian Lamb, Co-founder and Managing Director, Genesys Capital. 'We are pleased to recommit to the Genesys team and vision. Ontario is recognized as a leader in the life sciences sector and home to some of the sector's most innovative start-ups. The Genesys team, headquartered in Ontario, has a unique ability to identify high-potential companies and support them in becoming global leaders. We are excited about this continued partnership.' Steve Romanyshyn, President and Chief Executive Officer at Venture Ontario. 'Congratulations to the Genesys team. The government's approach of co-investing alongside private VC funds through the Venture Capital Catalyst Initiative is helping boost investment in emerging sectors. Today's announcement shows that Canadian life sciences innovation is going strong and getting the support it needs to compete.' The Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions. About Genesys Genesys Capital is a Venture Capital Fund based in Toronto, investing in early-stage life sciences opportunities in areas of unmet medical need. With over 25 years of investment experience adhering to a consistent company creation investment strategy, Genesys has become the most successful life sciences venture firm in Canada.
Yahoo
2 days ago
- Business
- Yahoo
Genesys Capital is Closing its Largest Fund to Date – Genesys Ventures IV LP
TORONTO & MONTREAL, June 11, 2025--(BUSINESS WIRE)--Genesys Capital ("Genesys") is pleased to announce the upcoming closing of Genesys Ventures IV LP ("Fund IV" or the "fund") to continue its successful track record of building Canadian life science companies in both the medtech and biotech sectors. Genesys welcomes new Limited Partners into Fund IV and thanks returning LP's that engaged early, maintained unwavering support through the fundraising process, and provided catalytic commitments of scale to the fund, in the current context of an unprecedented, ever-changing macro environment. Fund IV institutional investors include: BDC Capital, Export Development Canada (EDC), Fonds de solidarité de la Fédération des travailleurs et travailleuses du Québec (FTQ), HarbourVest, Royal Bank of Canada, Teralys Capital, Venture Ontario, and the Government of Canada's Venture Capital Catalyst Initiative (VCCI), which is administered by BDC Capital under its Life Sciences Stream. Limited Partner commitment to the Genesys franchise and the Genesys investment thesis of co-creating and investing in disruptive Canadian life science opportunities has paid off as Genesys has delivered class leading performance and increasing DPI across its successive funds. Genesys' value-added, partnership approach to working with scientific founders provides both capital and expertise to create companies that compete on a global scale. This has anchored Genesys as a local trusted source of deal flow for global syndicate partners and a first point of contact for repeat entrepreneurs. The team at Genesys has mastered its strategy that takes advantage of the opportunity that the innovation in Canada provides. Genesys has a distinguished history of delivering upper quartile returns across its previous funds and has stepped up into upper decile in its third fund. Notable recent exits include Inversago Pharma, which was acquired by Novo Nordisk for $1.4 billion, and Fusion Pharmaceuticals, which exited to AstraZeneca for $3.3 billion. These successes highlight Genesys' ability to generate fund level returns driven by local Canadian innovation. With this fund, Genesys Capital will continue to set the standard for life sciences venture capital in Canada, with a commitment to building world-class companies and delivering exceptional returns for its investors. Quotes "EDC is proud to support Genesys Capital, an important funder of companies advancing life sciences in Canada. As healthcare continues its rapid global expansion, Canada stands out with its skilled talent base, early-stage research and development capacity, and strong presence in medtech and biotech. Genesys' approach of building anchor companies will foster enduring ecosystem clusters in Canada, help drive innovation and strengthen Canada's global competitiveness in this growing sector. We look forward to seeing the transformative impact of this fund."Guillermo Freire, Senior Vice-President, Mid-Market Group, EDC. "The Fonds de solidarité FTQ's reinvestment in Genesys Capital demonstrates our confidence in a strategic player in life sciences venture capital. With its in-depth knowledge of the Quebec ecosystem and its ongoing support for emerging local companies in biotechnology, Genesys actively contributes to the sector's competitiveness and innovation."Maxime Pesant, Vice-President, Private Equity and Impact Investing – Life Sciences, at the Fonds de solidarité FTQ. "Accessing Canadian life sciences investments through a long-term partner like Genesys supports innovation in the market. It is also a strategic move to diversify the Canadian economy and ensure global competitiveness in health and biotechnology, sectors that we believe have historically delivered competitive returns for our investors."Senia Rapisarda, Managing Director, HarbourVest Partners. "It is a great time to be investing out of a new fund, and we are looking forward to continuing to create best in class biopharmaceutical and medical technology companies that leverage local innovations."Damian Lamb, Co-founder and Managing Director, Genesys Capital. "We are pleased to recommit to the Genesys team and vision. Ontario is recognized as a leader in the life sciences sector and home to some of the sector's most innovative start-ups. The Genesys team, headquartered in Ontario, has a unique ability to identify high-potential companies and support them in becoming global leaders. We are excited about this continued partnership."Steve Romanyshyn, President and Chief Executive Officer at Venture Ontario. "Congratulations to the Genesys team. The government's approach of co-investing alongside private VC funds through the Venture Capital Catalyst Initiative is helping boost investment in emerging sectors. Today's announcement shows that Canadian life sciences innovation is going strong and getting the support it needs to compete."The Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions. About Genesys Genesys Capital is a Venture Capital Fund based in Toronto, investing in early-stage life sciences opportunities in areas of unmet medical need. With over 25 years of investment experience adhering to a consistent company creation investment strategy, Genesys has become the most successful life sciences venture firm in Canada. Contact: Genesys Capital 123 Front Street West, Suite 1503, Toronto, ON M5J 2M2 info@ View source version on Contacts Jennifer Williamsjen@ (416) 598-4900
Yahoo
27-05-2025
- Business
- Yahoo
U.S. investors own Canada's future and that needs to change
Canada's next chapter depends on bold, immediate action. At the heart of this moment is our country's scale-up challenge. Our country has no shortage of promising startups, entrepreneurs and small- and medium-sized enterprises with world-class talent and ideas. What we lack, however, is the consistent Canadian capital to build these companies into globally competitive businesses. Currently, about two-thirds of all Canadian startup financing comes from U.S. investors. Why is Canada's future owned by Americans? Private capital plays a vital role in this equation. Investors do more than provide risk capital — they bring strategic guidance, global networks and the support Canadian companies need to compete and win in a global knowledge economy. That's why our venture capital market matters: It holds the key to unlocking our next phase of growth. Prime Minister Mark Carney acutely understands this intersection, given his previous leadership at the helm of two G7 central banks. Over the past six years, I've watched firsthand how venture capital and private equity have helped build stronger, more resilient and innovative companies. Even through the volatility of a global pandemic, capital deployment rose from $6.5 billion in venture capital and $21 billion in private equity in 2019, to $8 billion and $28 billion respectively by the end of 2024. Yes, the first quarter of 2025 has been soft, largely due to global economic uncertainty. Canada's challenge lies in the limited sources of capital that are allocated to venture capital and private equity. Such funding is required for Canada's startup and scale-up base to grow and create wealth that will remain in Canada. We need to tap into a broader base of capital. That means creating the right incentives for all types of investors — from individuals to corporations to institutional investors, such as Canada's Maple 8 pension plans — to allocate more capital into higher-risk, higher-reward asset classes like venture capital and private equity. The goal is simple: Steer more capital toward building the future economy, not just preserving the old one. This is where government must play a critical enabling role. Government alone cannot reorient the flow of capital, it cannot dictate where our pension plans invest, but it can create the signals that make risk-taking more attractive. That's what markets respond to. And markets are ready. We have a strong base to build from. Canada is home to over 70 highly innovative companies generating more than US$100 million in annual revenue, which is a sign of real market maturity. We've also seen the emergence of more than 40 venture capital-backed unicorns in just the past five years. The momentum is here. What's needed is national alignment and bold policy. The Liberal Party's platform unveiled on April 19 included a commitment to recapitalize the Venture Capital Catalyst Initiative (VCCI) by $1 billion — a very welcome signal. The VCCI is a public-private program first established as the Venture Capital Action Plan that directs financing to innovative Canadian firms and attracts significant investments from a diverse set of private sector investors. But even that is not enough on its own. What's needed now is a broader, more ambitious approach: one that better aligns government incentives with private markets and institutional capital, including our country's pension funds. All players, both public and private, must come to the table with a shared focus on capital deployment into the most productive parts of our economy. Canada holds all the elements necessary for innovative companies to soar. We have strong talent, sophisticated research, an abundance of energy and critical minerals. Canadian startups can help in building Canada's defence capabilities, they can help address food insecurity around the world, they have proven time and time again that they can produce life-changing therapeutics and can solve many of our environmental challenges. We simply to have to empower them to do this at scale. We need to inject clear policy objectives, procurement policies that grow home champions and attract the capital to these opportunities. This calls for national fiscal incentives that not only reward risk-taking but also enable the smooth flow of capital. We need more than a single measure — Canada requires a suite of robust, well-designed incentives that ensure growth opportunities are fully capitalized, and policies that support the movement of capital across provincial borders. What investors are looking for is a bold, broad-based strategy — clear signals that Canada is serious about driving innovation, scaling businesses, and unlocking nationwide economic potential. The Canadian Venture Capital and Private Equity Association's recent white paper, Tax & Innovation Policies to Incentivize Investment in Canada, released during the federal election campaign, outlines concrete, actionable policy recommendations to unlock investment. These recommendations were designed with a clear objective to make riskier — but more productive — asset classes more appealing by rewarding investors willing to take that risk. Chief among them is a bold recommendation to provide a preferential capital gains inclusion rate for productive investments, implement a federal tax incentive to break down barriers to inter-provincial capital flow, and a renewed commitment to public-private partnerships like VCCI that crowd in private capital at scale. Small deals dominate Canadian private equity this year OECD predicts Canadian economy will avoid recession, but will see flat growth in 2025 The stakes are high. We are living in a time of global uncertainty but also immense possibility. Canada cannot afford to sit back. The conditions for growth are here. The capital is here. The ambition is here. What we need now is bold, deliberate leadership to unlock it. We've laid a solid foundation, so why stop now? This isn't the time to ease up — it's the time to scale up. Kim Furlong is the CEO of the Canadian Venture Capital and Private Equity Association. She will be stepping down from the organization on July 2. Sign in to access your portfolio
